ArticleNature medicine2024
Risk-based lung cancer screening performance in a universal healthcare setting.
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.Public health reviews · 2026Pooled it
- Clinical value of combinedOncology reviews · 2026Pooled it
- LDCT uptake and determinants of lung cancer screening in Asia: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Integrating Deep Learning of Low-Dose CT Imaging With Clinical Data for Lung Cancer Risk Prediction.Chest · 2026Article
- CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.Molecular oncology · 2026Article
- Lobectomy, segmentectomy, and wedge resection for elderly patients with solid-predominant stage I NSCLC: survival, pulmonary function, and postoperative outcomes.Translational lung cancer research · 2026Article
- Article
- Estimating and Ranking of Common Cancers in South Africa's Eastern Cape and Mpumalanga Provinces: A Patient Survey in Three Referral Hospitals.International journal of environmental research and public health · 2026Article
- Baseline results from the Norwegian radiology-led lung cancer screening pilot.Acta oncologica (Stockholm, Sweden) · 2026Article
- Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.Annals of internal medicine · 2026Article
- Reducing bulky medical images via shape-texture decoupled deep neural networks.Nature communications · 2026Article
- Results of a Swiss community-based pilot study on low-dose ct lung cancer screening.BMC pulmonary medicine · 2026Article
- CCM-ITALUNG2 pilot on lung cancer screening in Italy: recruitment, integration with smoking cessation and baseline results.La Radiologia medica · 2026Article
- The lung cancer screening marathon after baseline: evidence from incidence nodules.European radiology · 2025Article
- Article
- Construction of a novel tool for predicting chronic obstructive pulmonary disease mortality in lung cancer patients.Scientific reports · 2025Article
- Structured narrative review on lung cancer screening: current evidence, clinical practice implications and implementation insights from a multidisciplinary task force and patient representatives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Review
- Survival prognostic nomogram for young metastatic non-small cell lung cancer: a study of the US SEER database and a Chinese cohort.Frontiers in oncology · 2025Article
- Research progress of nano-based drug delivery systems based on stimuli-responsive materials for the treatment of lung diseases.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, lung cancer is the leading cause of cancer death. Previous trials demonstrated that low-dose computed tomography lung cancer screening of high-risk individuals can reduce lung cancer mortality by 20% or more. Lung cancer screening has been approved by major guidelines in the United States, and over 4,000 sites offer screening. Adoption of lung screening outside the United States has, until recently, been slow. Between June 2017 and May 2019, the Ontario Lung Cancer Screening Pilot successfully recruited 7,768 individuals at high risk identified by using the PLCOm2012noRace lung cancer risk prediction model. In total, 4,451 participants were successfully screened, retained and provided with high-quality follow-up, including appropriate treatment. In the Ontario Lung Cancer Screening Pilot, the lung cancer detection rate and the proportion of early-stage cancers were 2.4% and 79.2%, respectively; serious harms were infrequent; and sensitivity to detect lung cancers was 95.3% or more. With abnormal scans defined as ones leading to diagnostic investigation, specificity was 95.5% (positive predictive value, 35.1%), and adherence to annual recall and early surveillance scans and clinical investigations were high (>85%). The Ontario Lung Cancer Screening Pilot provides insights into how a risk-based organized lung screening program can be implemented in a large, diverse, populous geographic area within a universal healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.